Receptor, EphA2

"Receptor, EphA2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An Eph family receptor found abundantly in tissues of epithelial origin. It is expressed in a diverse array of tissues during embryonic development, suggesting that it may play a role in embryogenesis. In adult tissues high levels of the receptor are expressed in the LUNG; SKIN; SMALL INTESTINE and OVARY.

Descriptor ID	D036104
MeSH Number(s)	D08.811.913.696.620.682.725.400.850.100 D12.776.543.750.630.500.100
Concept/Terms	Receptor, EphA2 Receptor, EphA2 Epithelial Cell Kinase Protein EphA2 Receptor EphA2-Tyrosine Kinase EphA2 Tyrosine Kinase EphA2 Receptor Tyrosine Kinase EphA2 Protein Mammary-Derived Tyrosine Kinase 2 Mammary Derived Tyrosine Kinase 2

Below are MeSH descriptors whose meaning is more general than "Receptor, EphA2".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
Receptors, Eph Family [D08.811.913.696.620.682.725.400.850]
Receptor, EphA2 [D08.811.913.696.620.682.725.400.850.100]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
Receptors, Eph Family [D12.776.543.750.630.500]
Receptor, EphA2 [D12.776.543.750.630.500.100]

Below are MeSH descriptors whose meaning is related to "Receptor, EphA2".

Below are MeSH descriptors whose meaning is more specific than "Receptor, EphA2".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptor, EphA2" by people in this website by year, and whether "Receptor, EphA2" was a major or minor topic of these publications.

Bar chart showing 40 publications over 15 distinct years, with a maximum of 6 publications in 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	1	0	1
2005	2	0	2
2006	3	0	3
2007	1	0	1
2008	2	0	2
2009	6	0	6
2010	2	1	3
2012	2	1	3
2013	3	1	4
2014	3	1	4
2015	2	0	2
2017	1	0	1
2018	3	0	3
2020	1	0	1
2021	2	2	4

Below are the most recent publications written about "Receptor, EphA2" by people in Profiles.

Fekadu S, Kanehiro Y, Kartika AV, Hamada K, Sakurai N, Mizote T, Akada J, Yamaoka Y, Iizasa H, Yoshiyama H. Gastric epithelial attachment of Helicobacter pylori induces EphA2 and NMHC-IIA receptors for Epstein-Barr virus. Cancer Sci. 2021 Nov; 112(11):4799-4811.

View in: PubMed
Wu Y, Huang J, Ivan C, Sun Y, Ma S, Mangala LS, Fellman BM, Urbauer DL, Jennings NB, Ram P, Coleman RL, Hu W, Sood AK. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021 10; 163(1):181-190.

View in: PubMed
Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, Petrilli LL, Vinci M, Ferrari F, Salviato E, Scarsella M, De Stefanis C, Weber G, Quintarelli C, De Angelis B, Brenner MK, Gottschalk S, Hoyos V, Locatelli F, Caruana I, Del Bufalo F. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).

View in: PubMed
Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112.

View in: PubMed
Hsu K, Middlemiss S, Saletta F, Gottschalk S, McCowage GB, Kramer B. Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther. 2021 04; 28(3-4):321-334.

View in: PubMed
Torres-Adorno AM, Vitrac H, Qi Y, Tan L, Levental KR, Fan YY, Yang P, Chapkin RS, Eckhardt BL, Ueno NT. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene. 2019 03; 38(12):2135-2150.

View in: PubMed
Fan J, Wei Q, Koay EJ, Liu Y, Ning B, Bernard PW, Zhang N, Han H, Katz MH, Zhao Z, Hu Y. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. Theranostics. 2018; 8(21):5986-5994.

View in: PubMed
Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, Wu MF, Orange JS, Sumazin P, Man TK, Joseph SK, Hegde M, Ahmed N. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018 03 27; 20(4):506-518.

View in: PubMed
Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017 06; 16(6):1114-1123.

View in: PubMed
Tsouko E, Wang J, Frigo DE, Aydogdu E, Williams C. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. Carcinogenesis. 2015 Sep; 36(9):1051-60.

View in: PubMed

People

Explore

Similar Concepts

Top Journals